RARA and acute promyelocytic leukemia: In particular, leukemia outcomes have been transformed by targeted therapies based on all-trans retinoic acid for the retinoic acid receptor alpha (RARα), arsenic trioxide for promyelocytic leukemia (PML)-RARα, imatinib for the BCR-ABL fusion gene, and ibrutinib for Bruton’s tyrosine kinase (RTK), as well as antibody-based therapies such as rituximab for CD-20 and gemtuzumab ozogamicin for CD33 (1, 2).